IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 07:11:09 2026-02-12 EST			5-day change	1st Jan Change
10.50 ^GBX	+2.44%		+2.44%	-10.64%

02-05	Ixico Names Chief Commercial Officer	MT
02-05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI

IXICO Plc Appoints Susan Lowther FCMA as Chief Financial Officer, Effective October 1, 2014

Published on 09/17/2014 at 02:01 am EDT

S&P Capital IQ

IXICO PLC

+2.44%

IXICO plc announced that Susan Lowther FCMA has been appointed to the board as Chief Financial Officer with effect from October 1, 2014. Susan (aged 54) was previously Group Chief Financial Officer and a director of Novacyt SA.

Latest news about IXICO plc

02-05	Ixico Names Chief Commercial Officer	MT
02-05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI
12-26	IXICO plc - Analyst/Investor Day
12-10	IXICO plc, 2025 Earnings Call, Dec 09, 2025
12-09	EARNINGS AND TRADING: Great Southern widens loss; MediaZest revenue up	AN
12-09	IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-09	Earnings Flash (IXI.L) Ixico plc Reports FY25 Revenue GBP6.5M	MT
12-01	IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025	CI
11-17	Ixico wins GBP3.7 million deal to support Huntington's Disease trial	AN
11-17	AIM WINNERS & LOSERS: OptiBiotix and Ixico rise on deal wins	AN
11-17	Uncertain trade as belated US jobs data looms	AN
11-17	Ixico announces phase 3 clinical trial contract win worth over 3.5 mln stg over four years	RE
11-17	IXICO plc Announces Global Phase 3 Clinical Trial Contract Win Worth over £3.5 Million	CI
25-10-16	Anglo Asian copper production rises, backs guidance	AN
25-10-16	Earnings Flash (IXI.L) Ixico Reports FY25 Revenue GBP6.5M	MT
25-10-15	Ixico Wins New Deal, Contract Extension Totaling GBP1 Million	MT
25-10-15	Ixico plc announces new contract and extension worth total of u1.2 million	RE
25-10-15	Ixico plc Announces New Blood Based Biomarker Contract Win and Contract Extension Worth A Total of £1.2 Million	CI
25-08-12	Ixico wins neuroimaging contracts worth over GBP1 million	AN
25-08-12	Ixico Wins Two New Commercial Neuroimaging Contracts	MT
25-08-12	IXICO signs £1.3 million neuroimaging contracts	RE
25-08-12	IXICO plc Announces Global Clinical Trial Contract Wins in Alzheimer's Disease and Friedreich's Ataxia	CI
25-07-22	Flowtech wins deals; SpaceandPeople revenue climbs	AN
25-07-22	Global Alzheimer?s Platform Foundation Announces Strategic Collaboration and Partnership with IXICO for the Transformative Bio-Hermes-002 Study	CI
25-07-22	Ixico to Acquire Full Data Rights to Global Alzheimer's Platform Foundation's New Study	MT

Chart IXICO plc

Duration

Period

IXI: Dynamic Chart

Company Profile

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

Employees

Sector

Biotechnology & Medical Research

Calendar

05-25 - Q2 2026 Earnings Release (Projected)

More about the company